Wee Joo Chng

Promiscuous Mutations Activate the Noncanonical NF-κB Pathway in Multiple Myeloma

Jonathan J. Keats, Rafaël Fonseca, Marta Chesi et al. · Cancer Cell · 2007 · 988 citations · Full text

Medicine, Cell Biology, Molecular Biology +11

Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group

Pieter Sonneveld, Hervé Avet‐Loiseau, Sagar Lonial et al. · Blood · 2016 · 929 citations · Full text

Medicine, Hematology, Oncology +15

Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study

Meletios Α. Dimopoulos, Philippe Moreau, Antonio Palumbo et al. · The Lancet Oncology · 2015 · 849 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group study

Shaji Kumar, J H Lee, Juan José Lahuerta et al. · Leukemia · 2011 · 721 citations

Medicine, Hematology, Pharmacotherapy +15

A common BIM deletion polymorphism mediates intrinsic resistance and inferior responses to tyrosine kinase inhibitors in cancer

King Pan Ng, Axel M. Hillmer, Charles Chuah et al. · Nature Medicine · 2012 · 554 citations

Medicine, Molecular Biology, Oncology +17